Total | Genoptix | Large Labs | Other Controls | p-value | |||
---|---|---|---|---|---|---|---|
Study population size | (N = 24,664) | (N = 1,387) | (N = 4,162) | (N = 19,115) | |||
Changes to chemotherapy | Within 30 days of starting chemotherapy | % | 4.58% | 6.68% | 7.37% | 0.91 | |
Within 31–60 days of starting chemotherapy | % | 1.78% | 3.68% | 5.12% | 0.001 | ||
Adjusted odds ratio within 60 days of starting chemotherapy | Odds ratio | 0.718 | 1.197 | ||||
Confidence interval | 0.472, 1.093 | 0.98, 1.463 | |||||
P-value | 0.1224 | 0.0784 | |||||
Logistic model adjusted for age, region (Northwest, South), Medicare, initial diagnosis (MM, other NHL, other hematologic cancer/conditions), baseline Charlson comorbidity score, and baseline chemotherapy. | |||||||
Testing paid cost PPPM - Post-index fixed 1-year Follow-up period | Bone marrow biopsy costs | Mean (SD) | $1,804.34 (12,424.61) | $149.54 (1,006.24) | $736.74 (5,638.49) | $2,156.87 (13,842.72) | <0.001 |
Bone marrow tests costs | Mean (SD) | $305.18 (596.83) | $1,130.03 (1,022.85) | $249.81 (383.29) | $257.39 (547.21) | <0.001 | |
Other cancer-related tests costs | Mean (SD) | $292.68 (897.24) | $109.31 (405.88) | $199.39 (653.65) | $326.30 (963.49) | <0.001 | |
Other hematological tests costs | Mean (SD) | $47.93 (258.88) | $20.97 (67.77) | $34.30 (184.72) | $52.85 (280.35) | <0.001 | |
Total testing costs | Mean (SD) | $2,449.16 (12,689.30) | $1,409.84 (1,674.85) | $1,214.87 (5,842.95) | $2,793.32 14,127.97) | <0.001 | |
Mean costs include individuals with zero costs | |||||||
Mean healthcare costs PPPM during 1-year fixed follow-up period by Service type | Pharmacy cost | Mean (SD) | $624.69 (1,309.22) | $571.42 (1,279.36) | $578.84 (1,214.31) | $638.53 (1,330.84) | 0.008 |
Medical costs | Mean (SD) | $8,556.06 (21,267.46) | $4,790.58 (9,286.12) | $5,830.33 (13,479.36) | $9,422.77 (23,117.31) | <0.001 | |
Ambulatory cost | Mean (SD) | $3,279.69 (5,288.34) | $2,042.87 (3,618.11) | $2,759.93 (4,467.36) | $3,482.60 (5,529.99) | <0.001 | |
Office costs | Mean (SD) | $1,370.38 (2,591.48) | $1,281.19 (2,468.00) | $1,516.33 (2,648.42) | $1,345.07 (2,586.69) | <0.001 | |
Outpatient cost | Mean (SD) | $1,909.31 (4,338.71) | $761.68 (2,157.14) | $1,243.60 (3,251.64) | $2,137.53 (4,626.67) | <0.001 | |
Emergency services cost | Mean (SD) | $54.10 (216.34) | $36.42 (120.02) | $40.09 (129.11) | $58.43 (235.87) | <0.001 | |
Inpatient cost | Mean (SD) | $4,742.55 (19,060.20) | $1,515.11 (7,315.71) | $2,664.49 (11,325.53) | $5,429.20 (20,851.55) | <0.001 | |
Other cost | Mean (SD) | $479.72 (2,746.48) | $1,196.18 (1,179.72) | $365.82 (1,200.40) | $452.54 (3,045.91) | <0.001 | |
Total cost | Mean (SD) | $9,180.74 (21,433.97) | $5,362.00 (9,492.76) | $6,409.17 (13,676.32) | $10,061.30 (23,281.54) | <0.001 | |
All-cause paid costs PPPM: Summary of multiple Regression model results | Paid costs-remainder year (excluding initial 30-day period) | Adjusted Costs | $6,019 | $6,649 | $7,801 | ||
Paid costs-1 year | Adjusted Costs | $8,202 | $7,711 | $10,302 | |||
GLM model, adjusting for gender, age, age2, region, final diagnosis, baseline Charlson comorbidity score, baseline chemotherapy, baseline radiation therapy, baseline inpatient stay, baseline number of bone marrow-related tests. |